MYC and neoplasm: Without the need for additional chemical conjugation, such a straightforward yet innovative strategy for the construction of redox‐responsive ARV@PDSA Nano‐PROTACs not only substantially enhances accumulation/responsive‐release in tumor regions and bioavailability but also concomitantly scavenges GSH to neutralize the microenvironment and amplify the anti‐tumor efficacy of ARV‐771 via c‐Myc‐related ferroptosis and cell cycle arrest pathways,[28, 29] potentiating future clinical translation.